Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
Key Highlights
- ➤INFORM-MS met dual primary endpoints in non-active secondary progressive multiple sclerosis
- ➤50 μg intranasal foralumab reduced microglial activation versus placebo, p=0.0168
- ➤INFORM-MS showed statistically significant improvements in fatigue as a secondary endpoint
- ➤Tiziana will present its corporate overview and Phase 2a results November 18, 2026
Expert Statements
Tanuja Chitnis, M.D. and principal investigator of the INFORM-MS trial
“”
Tarun Singhal, M.B.B.S, M.D., M.B.A., Founding Director, NeuroPET Program, Ann Romney Center for Neurologic Diseases
“”
Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board, Robert L. Kroc Professor of Neurology, Harvard Medical School, and Co-Director, Ann Romney Center for Neurologic Diseases, BWH
“”
BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London taking place from November 16-19, 2026.
The presentation will feature a corporate overview and discussion of the Company’s recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), following the Key Opinion Leader (KOL) call held on November 9, 2026.
Get started
Create a free account to read the full story.